15.75
-0.27 (-1.69%)
| Penutupan Terdahulu | 16.02 |
| Buka | 15.45 |
| Jumlah Dagangan | 1,860,641 |
| Purata Dagangan (3B) | 1,783,577 |
| Modal Pasaran | 1,608,279,808 |
| Harga / Buku (P/B) | 5.64 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 - 20 Aug 2025 |
| EPS Cair (TTM) | -9.28 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.64% |
| Nisbah Semasa (MRQ) | 3.49 |
| Aliran Tunai Operasi (OCF TTM) | -582.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -364.16 M |
| Pulangan Atas Aset (ROA TTM) | -96.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -198.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Biohaven Ltd. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 2.50 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 11.97% |
| % Dimiliki oleh Institusi | 91.84% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Dec 2024 | 5,620,271 |
| Bellevue Group Ag | 31 Dec 2024 | 2,040,853 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 68.00 (JP Morgan, 331.75%) | Beli |
| Median | 57.00 (261.91%) | |
| Rendah | 21.00 (RBC Capital, 33.33%) | Pegang |
| Purata | 52.60 (233.97%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 25.94 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 19 May 2025 | 21.00 (33.33%) | Pegang | 15.75 |
| 13 May 2025 | 54.00 (242.86%) | Beli | 19.51 | |
| Baird | 28 Apr 2025 | 57.00 (261.90%) | Beli | 21.74 |
| Morgan Stanley | 07 Mar 2025 | 63.00 (300.00%) | Beli | 29.86 |
| JP Morgan | 05 Mar 2025 | 68.00 (331.75%) | Beli | 30.97 |
| HC Wainwright & Co. | 04 Mar 2025 | 54.00 (242.86%) | Beli | 31.37 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia |
| 12 May 2025 | Pengumuman | Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments |
| 28 Apr 2025 | Pengumuman | Biohaven Announces Investment up to $600 Million by Oberland Capital |
| 05 Apr 2025 | Pengumuman | Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting |
| 03 Mar 2025 | Pengumuman | Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 |
| 03 Mar 2025 | Pengumuman | Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |